相关实验视频
Updated: Jun 12, 2025

07:04
Identifying PD-1/PD-L1 Inhibitors with Surface Plasmon Resonance Technology
Published on: May 2, 2025
251
登德罗宾通过调节肺癌中PD-1/PD-L1检查点通路来抑制瘤生长
Linmao Li1, Jiejin Nong1, Jingui Li1
1Department of Oncology, Affiliated Hospital of Youjiang Medical University for Nationalities, Baise, Guangxi, 533000, P.R. China
Current cancer drug targets
|September 19, 2024
概括
登德罗宾通过抑制PD-1/PD-L1通路来抑制肺癌的生长,增强抗瘤免疫力. 这种天然化合物没有毒性,提供了一个有前途的治疗途径.
科学领域:
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
- 在瘤学瘤学.
背景情况:
- 丹德罗宾是一种来自Dendrobium nobile的天然化物,具有抗瘤特性.
- 丹德罗宾抗肺癌作用的确切机制需要阐明.
研究的目的:
- 为了研究树突蛋白抗肺癌活性背后的分子机制.
- 在肺癌模型中,评估单独和与抗PD-L1疗法结合的树脂氨酸的疗效.
主要方法:
- 生物信息分析以确定肺癌中的树突蛋白标.
- 在体外细胞活力测试 (CCK-8) 和体内异种移植小鼠模型.
- 流细胞计,免疫组织化学和细胞因子分析以评估免疫反应和瘤标记物.
主要成果:
- 登德罗宾抑制了肺癌细胞的活力,并调节了PD-1/PD-L1检查点通路.
- 结合的树突蛋白和抗PD-L1疗法降低了瘤生长,Ki-67和PD-L1表达,同时增加了CD4+,CD8+T细胞和IL-2/IFN-γ水平.
- 登德罗宾在小鼠模型中没有显著的肝毒性.
结论:
- 登德罗宾通过向PD-1/PD-L1通路来抑制肺癌免疫逃生.
- 登德罗宾显示出作为肺癌治疗剂的潜力,特别是在与免疫检查点抑制剂相结合时.
相关概念视频
Abnormal Proliferation
4.5K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.5K
Inhibition of Cdk Activity
4.7K
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
4.7K
Interactions Between Signaling Pathways
6.2K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
Tumor Immunotherapy
491
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
491
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
The Intrinsic Apoptotic Pathway
6.4K
Internal cellular stress, such as cellular injury or hypoxia, triggers intrinsic apoptosis. The B-cell lymphoma 2 (Bcl-2) family of proteins are the primary regulators of the intrinsic apoptotic pathway. For example, during DNA damage, checkpoint proteins, such as Ataxia Telangiectasia Mutated (ATM protein) and Checkpoints Factor-2 (Chk2) proteins, are activated. These proteins phosphorylate p53 which further activates pro-apoptotic proteins, such as Bax, Bak, PUMA, and Noxa, and inhibits...
6.4K

